Skip to main navigation
Skip to search
Skip to main content
WashU Medicine Research Profiles Home
Help & FAQ
Link opens in a new tab
Search content at WashU Medicine Research Profiles
Home
Profiles
Departments, Divisions and Centers
Research output
Chemotherapy for advanced bladder cancer
B. J. Roth
Section of Medical Oncology
Institute of Clinical and Translational Sciences (ICTS)
Siteman Cancer Center
Research output
:
Contribution to journal
›
Review article
›
peer-review
48
Link opens in a new tab
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Chemotherapy for advanced bladder cancer'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Chemotherapy
100%
Cisplatin
100%
Advanced Bladder Cancer
100%
Combination Regimen
100%
Response Rate
50%
Advanced Disease
50%
Gemcitabine
50%
Moderate to Severe
50%
Paclitaxel
50%
Combination Chemotherapy
50%
Patient Survival
50%
Median Survival
50%
Ifosfamide
50%
Active Agent
50%
Methotrexate
50%
Doxorubicin
50%
Time to Progression
50%
Gallium Nitride
50%
Vinblastine
50%
Severe Toxicity
50%
Dose Intensity
50%
New Combination
50%
Advanced Urothelial Carcinoma
50%
Trimetrexate
50%
Medicine and Dentistry
Cisplatin
100%
Bladder Cancer
100%
Paclitaxel
50%
Combination Chemotherapy
50%
Ifosfamide
50%
Methotrexate
50%
Doxorubicin
50%
Transitional Cell Carcinoma
50%
Gemcitabine
50%
Vinblastine
50%
Gallium Nitrate
50%
Piritrexim
50%
Trimetrexate
50%
Diseases
50%
Pharmacology, Toxicology and Pharmaceutical Science
Chemotherapy
100%
Bladder Cancer
100%
Cisplatin
66%
Paclitaxel
33%
Ifosfamide
33%
Methotrexate
33%
Doxorubicin
33%
Gemcitabine
33%
Vinblastine
33%
Gallium Nitrate
33%
Transitional Cell Carcinoma
33%
Piritrexim
33%
Trimetrexate
33%
Diseases
33%